Skip to main content

Table 1 Patients’ characteristics

From: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Characteristics

N (%)

Sex

 Male

80 (26)

 Female

225 (74)

 Median age, years (range)

63 (28–87)

< 55 years

105 (34)

≥ 55 years

200 (66)

Pre-existing osteoporosis

 Yes

8 (3)

 No

297 (97)

Type of tumor

 Breast cancer

179 (59)

 Hematologic cancer

106 (35)

 Prostate cancer

20 (7)

Bone metastasis

 Yes

30 (10)

 No

275 (90)

Opioids

 Yes

13 (4)

 No

292 (96)

NSAIDs

 Yes

16 (5)

 No

289 (95)

Prior chemotherapy

 Yes

28 (9)

 No

277 (91)

Type of chemotherapy

 Adjuvant chemotherapy

149 (47)

 Chemotherapy alone

162 (53)

Type of prophylaxis

 Primary

251 (82)

 Secondary

54 (18)

Pegfilgrastim administration

 Day 2 or 3

129 (42)

 Days 4–7

176 (58)

  1. NSAIDs Non-steroidal anti-inflammatory drugs